Felbamate: Clinical and molecular aspects of a unique antiepileptic drug

Critical Reviews in Neurobiology

Volumn 12, Issue 3, 1998, Pages 205-222

  Brown, William M ^a   Aiken, Simon P ^b  

^a UNIVERSITY OF TASMANIA   (Australia)

^b UNIVERSITY OF ST ANDREWS   (United Kingdom)

Author keywords

Antiepileptic drug (AED); Aplastic anemia; Epilepsy; Felbamate; Liver failure; N methyl D aspartate (NMDA); Pharmacotherapy; Toxicity; aminobutyric acid (GABA)

Indexed keywords

4 AMINOBUTYRIC ACID; 4 AMINOBUTYRIC ACID RECEPTOR; ANTICONVULSIVE AGENT; BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE; CARBAMAZEPINE; ETHOSUXIMIDE; ETIRACETAM; EXCITATORY AMINO ACID; FELBAMATE; FOSPHENYTOIN SODIUM; GABAPENTIN; LAMOTRIGINE; LOSIGAMONE; MEPROBAMATE; OXCARBAZEPINE; PHENYTOIN; PICROTOXIN; RALITOLINE; REMACEMIDE; RUFINAMIDE; SCH 54388; STIRIPENTOL; TIAGABINE; TOPIRAMATE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID; VERATRIDINE; VIGABATRIN; ZONISAMIDE;

ADULT; AGED; APLASTIC ANEMIA; ATAXIA; BLOOD DYSCRASIA; CHILD; CLINICAL TRIAL; DIPLOPIA; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG TOXICITY; EPILEPSY; HEADACHE; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LENNOX GASTAUT SYNDROME; LIVER FAILURE; NAUSEA; NONHUMAN; PSYCHOSIS; REVIEW; TOXIC EPIDERMAL NECROLYSIS; VERTIGO; VISUAL IMPAIRMENT; VOMITING;

EID: 0032424051     PISSN: 08920915     EISSN: None     Source Type: Journal    
DOI: 10.1615/CritRevNeurobiol.v12.i3.30     Document Type: Review

References (190)

1. Porter, R. J., Therapy of epilepsy, Curr. Opin. Neurol. Neurosurg., 1, 206-211, 1988.
2. Shorvon, S. D., Epidemiology, classification, natural history, and genetics of epilepsy, Lancet, 336, 93-96, 1990.
3. Mosewich, R. K. and So, E. L., A clinical approach to the classification of seizures and epileptic syndromes, Mayo Clin. Proc., 71, 405-414, 1996.
4. So, E. L., Classifications and epidemiologic considerations of epileptic seizures and epilepsy, Neuroimaging Clin. N. Am., 5, 513-526, 1995.
5. Ozuna, J., Pharmacologic management of epilepsy: an update, J. Neurosci. Nursing, 29, 330-335, 1997.
6. Friedlander, W. J., Who was "the father of bromide treatment of epilepsy?, Arch. Neurol., 43, 505-507, 1986.
7. Sabers, A. and Gram, L., Drug treatment of epilepsy in the 1990s. Achievements and new developments, Drugs, 52, 483-493, 1996.
8. French, J., The long-term therapeutic management of epilepsy, Ann. Intern. Med., 120, 411-422, 1994.
9. Pledger, G. W. and Schmidt, D., Evaluation of antiepileptic drug efficacy. A review of clinical trial design, Drugs, 48, 498-509, 1994.
10. Curry, W. J. and Kulling, D. L., Newer antiepileptic drugs: gabapentin, lamotrigine, felbamate, topiramate, and fosphenytoin, Am. Fam. Physic., 57, 513-520, 1998.
11. Blum, D. E., New drugs for persons with epilepsy, Adv. Neurol., 76, 57-87, 1998.
12. Meldrum, B. S., Update on the mechanism of action of antiepileptic drugs, Epilepsia, 37, Suppl. 6, S4-S11, 1996.
13. Wilson, E. A. and Brodie, M. J., New antiepileptic drugs, Baillieres Clin. Neurol., 5, 723-747, 1996.
14. McLean, M. J., Schmutz, M., Wamil, A. W., Olpe, H. R., Portet, C., and Feldmann, K. F., Oxcarbazepine: mechanisms of action, Epilepsia, 35, Suppl. 3, S5-S9, 1994.
15. Schmutz, M., Brugger, F., Gentsch, C., McLean, M. J., and Olpe, H. R., Oxcarbazepine: preclinical anticonvulsant profile and putative mechanisms of action, Epilepsia, 35, Suppl. 5, S47-S50, 1994.
16. + currents: quantitative distinction from phenytoin and possible therapeutic implications, Mol. Pharmacol., 51, 1077-1083, 1997.
17. Rush, A. M. and Elliott, J. R., Phenytoin and carbamazepine: differential inhibition of sodium currents in small cells from adult rat dorsal root ganglia, Neurosci. Lett., 226, 95-98, 1997.
18. Song, J. H., Nagata, K., Huang, C. S., Yeh, J. Z., and Narahashi, T., Differential block of two types of sodium channels by anticonvulsants, Neuroreport, 7, 3031-3036, 1996.
19. Macdonald, R. L. and Kelly, K. M., Mechanisms of action of currently prescribed and newly developed antiepileptic drugs, Epilepsia, 35, Suppl. 4, S41-S50, 1994.
20. Macdonald, R. L. and Kelly, K. M., Antiepileptic drug mechanisms of action, Epilepsia, 36, Suppl. 2, S2-S12, 1995.
21. Macdonald, R. L. and Greenfield, L. J., Jr., Mechanisms of action of new antiepileptic drugs, Curr. Opin. Neurol., 10, 121-128, 1997.
22. Natsch, S., Hekster, Y. A., Keyser, A., Deckers, C. L., Meinardi, H., and Reiner, W. O., Newer anticonvulsant drugs; role of pharmacology, drug interactions and adverse reactions in drug choice, Drug Safety, 17, 228-240, 1997.
23. Adkins, J. C. and Noble, S., Tiagabine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the management of epilepsy, Drugs, 55, 437-460, 1998.
24. Sirven, J. I. and Liporace, J. D., New antiepileptic drugs. Overcoming the limitations of traditional therapy, Postgrad. Med., 102, 147-160, 1997.
25. Glazko, A. J., Discovery of phenytoin, Ther. Drug Monit., 8, 490-497, 1986.
26. Bazil, M. K. and Bazil, C. W., Recent advances in the pharmacotherapy of epilepsy, Clin. Ther., 19, 367-382, 1997.
27. Ramsay, R. E., Advances in the pharmacotherapy of epilepsy, Epilepsia, 34, Suppl. 5, S9-S16, 1993.
28. Leppik, I. E., Antiepileptic drugs in development: prospects for the near future, Epilepsia, 35, Suppl. 4, S29-S40, 1994.
29. Ben-Menachem, E., Soderfelt, B., Hamberger, A., Hedner, T., and Persson, L. I., Seizure frequency and CSF parameters in a double-blind placebo controlled trial of gabapentin in patients with intractable complex partial seizures, Epilepsy Res., 21, 231-236, 1995.
30. Ramsay, R. E., Clinical efficacy and safety of gabapentin, Neurology, 44, Suppl. 5, S23-S32, 1994.
31. Pellock, J. M., Overview of lamotrigine and the new antiepileptic drugs; the challenge, J. Child Neurol., 12, Suppl. 1, S48-S52, 1997.
32. Shorvon, S. and Stefan, H., Overview of the safety of newer antiepileptic drugs, Epilepsia, 38, Suppl. 1, S45-S51, 1997.
33. Dalby, N. O. and Nielsen, E. B., Comparison of the preclinical anticonvulsant profiles of tiagabine, lamotrigine, gabapentin, and vigabatrin, Epilepsy Res., 28, 63-72, 1997.
34. Perucca, E. and Bialer, M., The clinical pharmacokinetics of the newer antiepileptic drugs. Focus on topiramate, zonisamide, and tiagabine, Clin. Pharmacokinet., 31, 29-46, 1996.
35. Bialer, M., Johannessen, S. I., Kupferberg, H. J., Levy, R. H., Loiseau, P., and Perucca, E., Progress report on new antiepileptic drugs: a summary of the Third Eilat Conference, Epilepsy Res., 25, 299-319, 1996.
36. Stables, J. P., Bialer, M., Johannessen, S. I., Kupferberg, H. J., Levy, R. H., Loiseau, P., and Perucca, E., Progress report on new antiepileptic drugs. A summary of the Second Eilat Conference. Epilepsy Res., 22, 235-246, 1995.
37. Leach, J. P. and Brodie, M. J., New antiepileptic drugs - an explosion of activity, Seizure, 4, 5-17, 1995.
38. Tran, A., Vauzelle-Kervroedan, F., Rey, E., Pous, G., d'Athis, P., Chiron, C., Dulac, O., Renard, F., and Olive, G., Effect of stiripentol on carbamazepine plasma concentration and metabolism in epileptic children, Eur. J. Clin. Pharmacol., 50, 497-500, 1996.
39. Tran, A., Rey, E., Pons, G., Rousseau, M., d'Athis, P., Olive, G., Mather, G. G., Bishop, F. E., Wurden, C. J., Labroo, R., Trager, W. F., Kunze, K. L., Thummel, K. E., Vincent, J. C., Gillardin, J. M., Lepage, F., and Levy, R. H., Influence of stiripentol on cytochrome P450-mediated metabolic pathways in humans: in vitro and in vivo comparison and calculation of in vivo inhibition constants, Clin. Pharmacol. Ther., 62, 490-504, 1997.
40. Walker, M. C. and Patsalos, P. N., Clinical pharmacokinetics of new antiepileptic drugs, Pharmacol. Ther., 67, 351-384, 1995.
41. Dostal, L. A. and Anderson, J. A., Developmental toxicity study in rats treated with the anticonvulsant ralitoline, Teratology, 51, 11-19, 1995.
42. Kochak, G. M., Page, J. G., Buchanan, R. A., Peters, R., and Padgett, C. S., Steady-state pharmacokinetics of zonisamide, an antiepileptic agent for treatment of refractory complex partial seizures, J. Clin. Pharmacol., 38, 166-171, 1998.
43. Peters, D. H. and Sorkin, E. M., Zonisamide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in epilepsy, Drugs, 45, 760-787, 1993.
44. Leppik, I. E. and Wolff, D. L., The place of felbamate in the treatment of epilepsy, CNS Drugs, 4, 294-301, 1995.
45. Ludwig, B. J., Powell, L. S., and Berger, F. M., Carbamate derivatives related to meprobamate, J. Med. Chem., 12, 462-472, 1969.
46. Rho, J. M., Donevan, S. D., and Rogawski, M. A., Barbiturate-like actions of the propanediol dicarbamates felbamate and meprobamate, J. Pharmacol. Exp. Ther., 280, 1383-1391, 1997.
47. Leppik, I. E., Felbamate, Epilepsia, 36, Suppl. 2, S66-S72, 1995.
48. Reidenberg, P., Glue, P., Banfield, C., Colucci, R., Meehan, J., Radwanski, E., Mojavarian, P., Lin, C.-C., Nezamis, J., Guillaume, M., and Affrime, M. B., Effects of felbamate on the pharmacokinetics of phenobarbital, Clin. Pharmacol. Ther., 58, 279-287, 1995.
49. Adusumalli, V. E., Wichmann, J. K., Kucharczyk, N., and Sofia, R. D., Distribution of the anticonvulsant felbamate to cerebrospinal fluid and brain tissue of adult and neonatal rats, Drug Metab. Dispos., 21, 1079-1085, 1993.
50. Thompson, C. D., Kinter, M. T., and Macdonald, T. L., Synthesis and in vitro reactivity of 3-carbamoyl-2-phenylpropionaldehyde and 2-phenylpropenal: putative reactive metabolites of felbamate, Chem. Res. Toxicol., 9, 1225-1229, 1996.
51. Thompson, C. D., Gulden, P. H., and Macdonald, T. L., Identification of modified atropaldehyde mercapturic acids in rat and human urine after felbamate administration, Chem. Res. Toxicol., 10, 457-462, 1997.
52. Smith, R. D., Grzelak, M. E., and Coffin, V. L., Reduction of dizocilpine and scopolamine-induced deficits in avoidance responding by SCH 54388, a metabolite of felbamate, Pharmacol. Biochem. Behav., 58, 657-664, 1997.
53. Frey, H. H. and Bartels, I., Felbamate and meprobamate: a comparison of their anticonvulsant properties, Epilepsy Res., 27, 151-164, 1997.
54. A receptor, Ann. Neurol., 35, 229-234, 1994.
55. Subramaniam, S., Rho, J. M., Penix, L., Donevan, S. D., Fielding, R. P., and Rogawski, M. A., Felbamate block of the N-methyl-D-aspartate receptor, J. Pharmacol. Exp. Ther., 273, 878-886, 1995.
56. Kanthasamy, A. G., Matsumoto, R. R., Gunasekar, P. G., and Truong, D. D., Excitoprotective effect of felbamate in cultured cortical neurons, Brain Res., 705, 97-104, 1995.
57. +-stimulated release of glutamate from mouse cortex, Eur. J. Pharmacol., 315, 285-288, 1996.
58. Domenici, M. R., Sagratella, S., Ongini, E., Longo, R., and de Carolis, A. S., Felbamate displays in vitro antiepileptic effects as a broad spectrum excitatory amino acid receptor antagonist, Eur. J. Pharmacol., 271, 259-263, 1994.
59. 2+ concentration, Eur. J. Pharmacol., 289, 229-233, 1995.
60. Pisani, A., Stefani, A., Siniscalchi, A., Mercuri, N. B., Nernardi, G., and Calabresi, P., Electrophysiological actions of felbamate on rat striatal neurones, Br. J. Pharmacol., 116, 2053-2061, 1995.
61. De Sarro, G., Ongini, E., Bertorelli, R., Aguglia, U., and de Sarro, A., Excitatory amino acid neurotransmission through both NMDA and non-NMDA receptors is involved in the anticonvulsant activity of felbamate in DBA/2 mice, Eur. J. Pharmacol., 262, 11-19, 1994.
62. Nagel, T. R. and Schunk, J. E., Felbamate overdose: a case report and discussion of a new antiepileptic drug, Pediatr. Emerg. Care, 11, 369-371, 1995.
63. A) receptor, J. Pharmacol. Exp. Ther., 277, 1784-1792, 1996.
64. Xiong, Z. Q. and Stringer, J. L., Effects of felbamate, gabapentin and lamotrigine on seizure parameters and excitability in the rat hippocampus, Epilepsy Res., 27, 187-194, 1997.
65. Hunter, J. C., Gogas, K. R., Hedley, L. R., Jacobson, L. O., Kassotakis, L., Thompson, J., and Fontana, D. J., The effect of novel anti-epileptic drugs in rat experimental models of acute and chronic pain, Eur. J. Pharmacol., 324, 153-160, 1997.
66. + channels from human and rat brain, Eur. J. Pharmacol., 316, 373-377, 1996.
67. Peterson, S. L., The effect on maximal electroshock seizures induced by GABA agents and antiepileptic drugs microfused into the nucleus reticularis pontis oralis, Epilepsy Res., 25, 161-167, 1996.
68. Pugliese, A. M. and Corradetti, R., Effects of the antiepileptic drug felbamate on long-term potentiation in the CA1 region of rat hippocampal slices, Neurosci. Lett., 215, 21-24, 1996.
69. Calabresi, P., Siniscalchi, A., Pisani, A., Stefani, A., and Mercuri, N. B., A field potential analysis on the effects of lamotrigine, GP 47779, and felbamate in neocortical slices, Neurology, 47, 557-562, 1996.
70. Shuaib, A., Waqaar, T., Ijaz, M. S., Kanthan, R., Wishart, T., and Hewlett, W., Neuroprotection with felbamate: a 7- and 28-day study in transient forebrain ischemia in gerbils, Brain Res., 727, 65-70, 1996.
71. Bertorelli, R., Smirne, S., Adami, M., de Rino, F., and Iannaccone, S., Neuroprotective effects of felbamate on global ischaemia in Mongolian gerbils, Pharmacol. Res., 34, 59-64, 1996.
72. Wasterlain, C. G., Adams, L. M., Wichmann, J. K., and Sofia, R. D., Felbamate protects CA1 neurons from apoptosis in a gerbil model of global ischemia, Stroke, 27, 1236-1240, 1996.
73. Wallis, R. A. and Panizzon, K. L., Felbamate neuroprotection against CA1 traumatic neuronal injury, Eur. J. Pharmacol., 294, 475-482, 1995.
74. Giorgi, O., Carboni, G., Frau, V., Orlandi, M., Valentini, V., Feldman, A., and Corda, M. G., Anticonvulsant effect of felbamate in the pentylenetetrazole kindling model of epilepsy in the rat, Naunyn Schmiedebergs Arch. Pharmacol., 354, 173-178, 1996.
75. Libri, V., Constanti, A., Zibetti, M., and Nistico, S., Effects of felbamate on muscarinic and metabotropic-glutamate agonist-mediated responses and magnesium-free or 4-aminopyridine-induced epileptiform activity in guinea pig olfactory cortex neurons in vitro, J. Pharmacol. Exp. Ther., 277, 1759-1769, 1996.
76. Stefani, A., Calabresi, P., Pisani, A., Mercuri, N. B., Siniscalchi, A., and Bernardi, G., Felbamate inhibits dihydropyridine-sensitive calcium channels in central neurons, J. Pharmacol. Exp. Ther., 277, 121-127, 1996.
77. Cornford, E. M., Truong, H.-V. M., Sofia, R. D., and Kucharczyk, N., Distribution of felbamate in the brain, Epilepsia, 37, 15-18, 1996.
78. Swinyard, E. A., Sofia, R. D., and Kupferberg, H. J., Comparative anticonvulsant activity and neurotoxicity of felbamate and four prototype antiepileptic drugs in mice and rats, Epilepsia, 27, 27-34, 1986.
79. A receptor system, Epilepsia, 32, 389-391, 1991.
80. Leppik, I. E., Dreifuss, F. E., Pledger, G. W., Graves, N. M., Santilli, N., Drury, I., Tsay, J. Y., Jacobs, M. P., Bertram, E., Cereghino, J. J., Cooper, G., Sahlroot, J. T., Sheridan, P., Ashworth, M., Lee, S. I., and Sierzant, T. L., Felbamate for partial seizures: results of a controlled clinical trial, Neurology, 41, 1785-1789, 1991.
81. McCabe, R. T., Wasterlain, C. G., Kucharczyk, N., Sofia, R. D., and Vogel, J. R., Evidence for anticonvulsant and neuroprotectant action of felbamate mediated by strychnine-insensitive glycine receptors, J. Pharmacol. Exp. Ther., 264, 1248-1252, 1993.
82. White, H. S., Wolf, H. H., Swinyard, E. A., Skeen, G. A., and Sofia, R. D., A neuropharmacological evaluation of felbamate as a novel anticonvulsant, Epilepsia, 33, 564-572, 1992.
83. White, H. S., Harmsworth, W. L., Sofia, R. D., and Wolf, H. H., Felbamate modulates the strychnine-insensitive glycine receptor, Epilepsy Res., 20, 41-48, 1995.
84. Wamsley, J. K., Sofia, R. D., Faull, R. L. M., Narang, N., Ary, T., Gan, X.-D., and McCabe, R. T., Felbamate: interaction with glycine receptors in human cerebral cortex, Proc. West. Pharmacol. Soc., 37, 81-83, 1994.
85. Longo, R., Domenici, M. R., de Carolis, A. S., and Sagratella, S., Felbamate selectively blocks in vitro hippocampal kainate-induced irreversible electrical changes, Life Sci., 56, PL409-PL414, 1995.
86. Behnke, C. E. and Reddy, M. N., Determination of felbamate concentration in pediatric samples by high-performance liquid chromatography, Ther. Drug Monit., 19, 301-306, 1997.
87. Kelley, M. T., Walson, P. D., Cox, S., and Dusci, L. J., Population pharmacokinetics of felbamate in children, Ther. Drug Monit., 19, 29-36, 1997.
88. Banfield, C. R., Zhu, G. R., Jen, J. F., Jensen, P. K., Schumaker, R. C., Perhach, J. L., Affrime, M. B., and Glue, P., The effect of age on the apparent clearance of felbamate: a retrospective analysis using non-linear mixed-effects modeling, Ther. Drug Monit., 18, 19-29, 1996.
89. Graves, N. M., Ludden, T. M., Holmes, G. B., Fuerst, R. H., and Leppik, I. E., Pharmacokinetics of felbamate, a novel antiepileptic drug: application of mixed-effect modeling to clinical trials, Pharmacotherapy, 9, 372-376, 1989.
90. Palmer, K. J. and McTavish, D., Felbamate, Drugs, 45, 1041-1065, 1993.
91. Riva, R., Albani, F., Contin, M., and Baruzzi, A., Pharmacokinetic interactions between antiepileptic drugs. Clinical considerations, Clin. Pharmacokinet., 31, 470-493, 1996.
92. Rambeck, B., Specht, U., and Wolf, P., Pharmacokinetic interactions of the new antiepileptic drugs, Clin. Pharmacokinet., 31, 309-324, 1996.
93. Fuerst, R. H., Graves, N. M., Leppik, I. E., Brundage, R. C., Holmes, G. B., and Remmel, R. P., Felbamate increases phenytoin but decreases carbamazepine concentrations, Epilepsia, 29, 488-491, 1988.
94. Wagner, M. L., Graves, N. M., Leppik, I. E., Remmel, R. P., Shumaker, R. C., Ward, D. L., and Perhach, J. L., The effect of felbamate on valproic acid disposition, Clin. Pharmacol. Ther., 56, 494-502, 1994.
95. Hooper, W. D., Franklin, M. E., Glue, P., Banfield, C. R., Radwanski, E., McLaughlin, D. B., McIntyre, M. E., Dickinson, R. G., and Eadie, M. J., Effect of felbamate on valproic acid disposition in healthy volunteers: inhibition of beta-oxidation, Epilepsia, 37, 91-97, 1996.
96. Hussein, G., Troupin, A. S., and Montouris, G., Gabapentin interaction with felbamate, Neurology, 47, 1106, 1996.
97. Albani, F., Theodore, W. H., Washington, P., Devinsky, O., Bromfield, E., Porter, R. J., and Nice, F. J., Effect of felbamate on plasma levels of carbamazepine and its metabolites, Epilepsia, 32, 130-132, 1991.
98. Spina, E., Pisani, F., and Perucca, E., Clinically significant pharmacokinetic drug interactions with carbamazepine. An update, Clin. Pharmacokinet., 31, 198-214, 1996.
99. Gidal, B. E., Kanner, A., Maly, M., Rutecki, P., and Lensmeyer, G. L., Lamotrigine pharmacokinetics in patients receiving felbamate, Epilepsy Res., 27, 1-5, 1997.
100. Colucci, R., Glue, P., Holt, B., Banfield, C., Reidenberg, P., Meehan, J. W., Pai, S., Nomeir, A., Lim, J., Lin, C.-C., and Affrime, M. B., Effect of felbamate on the pharmacokinetics of lamotrigine, J. Clin. Pharmacol., 36, 634-638, 1996.
101. Reidenberg, P., Glue, P., Banfield, C., Colucci, R., Meehan, J., Rey, E., Radwanski, E., Nomeir, A., Lim, J., Lin, C.-C., Guillaume, M., and Affrime, M. B., Pharmacokinetic interaction studies between felbamate and vigabatrin, Br. J. Clin. Pharmacol., 40, 157-160, 1995.
102. Wilensky, A. J., Friel, P. N., Ojemann, L. M., Kupferberg, H. J., and Levy, R. H., Pharmacokinetics of W-554 (ADD 03055) in epileptic patients, Epilepsia, 26, 602-606, 1985.
103. Wagner, M. L., Remmel, R. P., Graves, N. M., and Leppik, I. E., Effect of felbamate on carbamazepine and its major metabolites, Clin. Pharmacol. Ther., 53, 536-543, 1993.
104. Post, R. M., Uhde, T. W., and Wolff, E. A., Profile of clinical efficacy and side effects of carbamazepine in psychiatric illness: relationship to blood and CSF levels of carbamazepine and its -10,11-epoxide metabolite, Acta Psychiatr. Scand. Suppl., 313, 104-120, 1984.
105. Patsalos, P. N., Stephenson, T. J., Krishna, S., Elyas, A. A., Lascelles, P. T., and Wiles, C. M., Side-effects induced by carbamazepine-10,11-epoxide, Lancet, 2, 1432, 1985.
106. Bennett, G. D., Amore, B. M., Finnell, R. H., Wlodarczyk, B., Kalhorn, T. F., Skiles, G. L., Nelson, S. D., and Slattery, J. T., Teratogenicity of carbamazepine-10, 11-epoxide and oxcarbazepine in the SWV mouse, J. Pharmacol. Exp. Ther., 279, 1237-1242, 1996.
107. Tomson, T., Almkvist, O., Nilsson, B. Y., Svensson, J. O., and Bertilsson, L., Carbamazepine-10,11-epoxide in epilepsy. A pilot study, Arch. Neurol., 47, 888-892, 1990.
108. Levy, R. H., Cytochrome P450 isozymes and antiepileptic drug interactions, Epilepsia, 36, Suppl. 5, S8-S13, 1995.
109. Glue, P., Banfield, C. R., Perhach, J. L., Mather, G. G., Racha, J. K., and Levy, R. H., Pharmacokinetic interactions with felbamate. In vitro-in vivo correlation, Clin. Pharmacokinet., 33, 214-224, 1997.
110. Richens, A., Banfield, C. R., Salfi, M., Nomeir, A., Lin, C.-C., Jensen, P., Affrime, M. B., and Glue, P., Single and multiple dose pharmacokinetics of felbamate in the elderly, Br. J. Clin. Pharmacol., 44, 129-134, 1997.
111. Glue, P., Sulowicz, W., Colucci, R., Banfield, C., Pai, S., Lin, C.-C., and Affrime, M. B., Single-dose pharmacokinetics of felbamate in patients with renal dysfunction, Br. J. Clin. Pharmacol., 44, 91-93, 1997.
112. Bourgeois, B. F., Felbamate in the treatment of partial-onset seizures, Epilepsia, 35, Suppl. 5, S58-S61, 1994.
113. Burdette, D. E. and Sackellares, J. C., Felbamate pharmacology and use in epilepsy, Clin. Neuropharmacol., 17, 389-402, 1994.
114. Pellock, J. M. and Boggs, J. G., Felbamate: a unique anticonvulsant, Drugs Today, 31, 9-17, 1995.
115. Brodie, M. J. and Pellock, J. M., Taming the brain storms: felbamate updated, Lancet, 346, 918-919, 1995.
116. Stafstrom, C. E., The use of felbamate to treat infantile spasms, J. Child Neurol., 11, 170-171, 1996.
117. Hurst, D. L. and Rolan, T. D., The use of felbamate to treat infantile spasms, J. Child Neurol., 10, 134-136, 1995.
118. Hosain, S., Nagarajan, L., Carson, D., Solomon, G., Mast, J., and Labar, D., Felbamate for refractory infantile spasms, J. Child Neurol., 12, 466-468, 1997.
119. Mellick, G. A., Hemifacial spasm: successful treatment with felbamate, J. Pain Symptom. Mgmt., 10, 392-395, 1995.
120. Glauser, T. A., Olberding, L. S., Titanic, M. K., and Piccirillo, D. M., Felbamate in the treatment of acquired epileptic aphasia, Epilepsy Res., 20, 85-89, 1995.
121. Cheshire, W. P., Felbamate relieved trigeminal neuralgia, Clin. J. Pain, 11, 139-142, 1995.
122. Pugliese, A. M., Passani, M. B., Pepeu, G., and Corradetti, R., Felbamate decreases synaptic transmission in the CA1 region of rat hippocampal slices, J. Pharmacol. Exp. Ther., 279, 1100-1108, 1996.
123. Escueta, A. V. D., Mattson, R. H., Smith, D. B., Cramer, J. A., and Collins, J. F., Principles in designing clinical trials for antiepileptic drugs, Neurology, 33, Suppl. 1, 8-13, 1983.
124. Mattson, R. H., Cramer, J. A., Escueta, A. V. D., Smith, D. B., Collins, J. F., Browne, T. R., Crill, W. E., Homan, R. W., Mayersdorf, A., McCutchen, C. B., McNamara, J. O., Rosenthal, N. P., Treiman, D. M., Wilder, B. J., Williamson, P. D., and Young, L. M., A design for the prospective evaluation of the efficacy and toxicity of antiepileptic drugs in adult, Neurology, 33, Suppl. 1, 14-25, 1983.
125. Mignot, G., Drug trials in epilepsy; new drugs have been poorly assessed, Br. Med. J., 313, 1158, 1996.
126. DeGiorgio, C. M., Lopez, J. E., Lekht, Z. N., and Rabinowicz, A. L., Status epilepticus induced by Felbatol withdrawal, Neurology, 45, 1021-1022, 1995.
127. Group for the Evaluation of Cinromide in Lennox-Gastaut Syndrome, Double-blind, placebo-controlled evaluation of cinromide in patients with the Lennox-Gastaut syndrome, Epilepsia, 30, 422-429, 1989.
128. Felbamate Study Group in Lennox-Gastaut Syndrome, Efficacy of felbamate in childhood epileptic encephalopathy (Lennox-Gastaut syndrome), N. Engl. J. Med., 328, 29-33, 1993.
129. Rodin, E. A., Rim, C. S., and Rennick, P. M., The effect of carbamazepine on patients with psychomotor epilepsy; results of a double blind trial, Epilepsia, 15, 547-561, 1974.
130. Devinsky, O., Faught, R. E., Wilder, B. J., Kanner, A. M., Kamin, M., Kramer, L. D., and Rosenberg, A., Efficacy of felbamate monotherapy in patients undergoing presurgical evaluation of partial seizures, Epilepsy Res., 20, 241-246, 1995.
131. Bourgeois, B. F., Leppik, I. E., Sackellares, J. C., Laxer, K., Lesser, R. Messenheimer, J. A., Kramer, L. D., Kamin, M., and Rosenberg, A., Felbamate: a double-blind controlled trial in patients undergoing presurgical evaluation of partial seizures, Neurology, 43, 693-696, 1993.
132. Jensen, P. K., Felbamate in the treatment of refractory partial-onset seizures, Epilepsia, 34, Suppl. 7, S25-S29, 1993.
133. Theodore, W. H., Raubertas, R. F., Porter, R. J., Nice, F., Devinsky, O., Reeves, P., Bromfield, E., Ito, B., and Balish, M., Felbamate: a clinical trial for complex partial seizures, Epilepsia, 32, 392-397, 1991.
134. Sachdeo, R., Kramer, L. D., Rosenberg, A., and Sachdeo, S., Felbamate monotherapy: controlled trial in patients with partial onset seizures, Ann. Neurol., 32, 386-392, 1992.
135. Faught, E., Sachdeo, R. C., Remler, M. P., Chayasirisobhon, S., Iragui-Madoz, V. J., Ramsay, R. E., Sutula, T. P., Kanner, A., Harner, R. N., Kuzniecky, R., Kramer, L. D., Kamin, M., and Rosenberg, A., Felbamate monotherapy for partial-onset seizures: an active-control trial, Neurology, 43, 688-692, 1993.
136. Avanzini, G., Canger, R., Dalla Bernardina, B., and Vigevano, F., Felbamate in therapy-resistant epilepsy: an Italian experience, Epilepsy Res., 25, 249-255, 1996.
137. Li, L. M., Nashef, L., Moriarty, J., Duncan, J. S., and Sander, J. W., Felbamate as add-on therapy, Eur. Neurol., 36, 146-148, 1996.
138. Carmant, L., Holmes, G.L., Sawyer, S., Rifai, N., Anderson, J., and Mikati, M. A., Efficacy of felbamate in therapy for partial epilepsy in children, J. Pediatr. 125, 481-486, 1994.
139. Holmes, G. L., Diagnosis and management of seizures in children. Major Problems in Clinical Pediatrics, vol. 30, W. B. Saunders, Philadelphia, PA, 1987.
140. Commission on Classification and Terminology of the International League Against Epilepsy, Proposal for revised classification of epilepsies and epileptic syndromes, Epilepsia, 30, 389-399, 1989.
141. Jensen, P. K., Felbamate in the treatment of Lennox-Gastaut syndrome, Epilepsia, 35, Suppl. 5, S54-S57, 1994.
142. Nightingale, S. L., From the Food and Drug Administration, J. Am. Med. Assoc., 272, 995, 1994.
143. Pennell, P. B., Ogaily, M. S., and Macdonald, R. L., Aplastic anemia in a patient receiving felbamate for complex partial seizures, Neurology, 45, 456-460, 1995.
144. Anon, Aplastic anemia and felbamate withdrawal, Am. Fam. Physic., 50, 700, 1994.
145. O'Neil, M. G., Perdun, C. S., Wilson, M. B., McGown, S. T., and Patel, S., Felbamate-associated fatal acute hepatic necrosis, Neurology, 46, 1457-1459, 1996.
146. Ney, G. C., Schaul, N., Loughlin, J., Rai, K., and Chandra, V., Thrombocytopenia in association with adjunctive felbamate use, Neurology, 44, 980-981, 1994.
147. Farrington, E., Felbamate: restrictions on use, Pediatr. Nurs., 21, 188-200, 1995.
148. Heydorn, W. E., Felbamate - rise and fall of a novel antiepilepsy compound, Expert Opin. Invest. Drugs, 3, 1205-1208, 1994.
149. Travaglini, M. T., Morrison, R. C., Ackerman, B. H., Haith, L. R., Jr., and Patton, M. L., Toxic epidermal necrolysis after initiation of felbamate therapy, Pharmacotherapy, 15, 260-264, 1995.
150. Storb, R., Aplastic anemia, J. Intraven. Nurs., 20, 317-322, 1997.
151. Young, N. S. and Maciejewski, J., The pathophysiology of acquired aplastic anemia, N. Engl. J. Med., 336, 1365-1372, 1997.
152. Kaufman, D. W., Kelly, J. P., Jurgelon, J. M., Anderson, T., Issaragrisil, S., Wiholm, B.-E., Young, N. S., Leaverton, P., Levy, M., and Shapiro, S., Drugs in the aetiology of agranulocytosis and aplastic anaemia, Eur. J. Haematol. Suppl., 51, 23-30, 1996.
153. Lubran, M. M., Hematologic side effects of drugs, Ann. Clin. Lab. Sci., 19, 114-121, 1989.
154. Gerson, W. T., Fine, D. G., Spielberg, S. P., and Sensenbrenner, L. L., Anticonvulsant-induced aplastic anemia: increased susceptibility to toxic drug metabolites in vitro, Blood, 61, 889-893, 1983.
155. Tagawa, T., Sumi, K., Itagaki, Y., Tanabe, Y., and Fujii, F., Aplastic anemia in a patient treated with carbamazepine monotherapy, J. Jap. Epilepsy Soc., 13, 233-236, 1995.
156. Sobotka, J. L., Alexander, B., and Cook B. L., A review of carbamazepine's hematologic reactions and monitoring recommendations, DICP Ann. Pharmacother., 24, 1214-1219, 1990.
157. Marti, J. and Garcia-Martin, C., Anemia aplasica por carbamacepina, Neurologia, 4, 221-222, 1989.
158. Durelli, L., Massazza, U., and Cavallo R., Carbamazepine toxicity and poisoning: incidence, clinical features, and management, Med. Toxicol. Adverse Drug Exp., 4, 95-107, 1989.
159. Franceschi, M., Ciboddo, G., Truci, G., Borri, A., and Canal N., Fatal aplastic anemia in a patient treated with carbamazepine, Epilepsia, 29, 582-558, 1988.
160. Moore, N. C., Lerer, B., Meyendorff, E., and Gershon, S., Three cases of carbamazepine toxicity, Am. J. Psychiatry, 142, 974-975, 1985.
161. Tomita, S., Kurokawa, T., Ueda, K., and Higuchi, S., Aplastic anaemia induced by intravenous phenytoin and lidocaine administration, Eur. J. Pediatr., 144, 207-208, 1985.
162. Seip, M., Aplastic anemia during ethosuximide medication. Treatment with bolus-methylprednisolone, Acta Paediatr. Scand., 72, 927-929, 1983.
163. Massey, G. V., Dunn, N. L., Heckel, J. L., Myer, E. C., and Russell, E. C., Aplastic anemia following therapy for absence seizures with ethosuximide, Pediatr. Neurol., 11, 59-61, 1994.
164. Iwai, A., Iwai, T., Furukawa, S., Hamada, Y., and Jofuku, N., Ethosuximide-induced aplastic anemia successfully treated with bolus methylprednisolone, Iryo Jap. J. Natl. Med. Serv., 45, 676-678, 1991.
165. Kao, T.-W., Hung, C.-C., Chen, Y.-C., and Tien, H.-F., Ticlopidine-induced aplastic anemia: report of three Chinese patients and review of the literature, Acta Haematol., 98, 211-213, 1997.
166. Shapiro, C. M. and Walk, D., Aplastic anemia associated with ticlopidine, Neurology, 47, 300, 1996.
167. Dunn, P. O., Aplastic anemia with ticlopidine therapy in two Chinese patients, Ann. Pharmacother., 30, 547, 1996.
168. Robbana-Barnat, S., Decloitre, F., Frayssinet, C., Seigneurin, J. M., Toucas, L., and Lafarge-Frayssinet, C., Use of human lymphoblastoid cells to detect the toxic effect of chloramphenicol and metabolites possibly involved in aplastic anemia in man, Drug Chem. Toxicol., 20, 239-253, 1997.
169. Fernandez, F. J., Rodriguez-Vidigal, F. F., Ledesma, V., Cabanillas, Y., and Vagace, J. M., Aplastic anemia during treatment with albendazole, Am. J. Hematol., 53, 53-54, 1996.
170. Escobar-Morreale, H. F., Bravo, P., Garcia-Robles, R., Garcia-Larana J., De La Calle H., and Sancho J. M., Methimazole-induced severe aplastic anemia: unsuccessful treatment with recombinant human granulocyte-monocyte colony-stimulating factor, Thyroid, 7, 67-70, 1997.
171. Bishara, J., Dux, S., and Pitlik, S., Methimazole-induced aplastic anemia, Ann. Pharmacother., 30, 684, 1996.
172. Furst, S. M. and Uetrecht, J. P., The effect of carbamazepine and its reactive metabolite, 9-acridine carboxaldehyde, on immune cell function in vitro, Int. J. Immunopharmacol., 17, 445-452, 1995.
173. Tohen, M., Castillo, J., Baldessarini, R. J., Zarate, C., Jr., and Kando, J. C., Blood dyscrasias with carbamazepine and valproate: a pharmacoepidemiological study of 2,228 patients at risk, Am. J. Psychiatry, 152, 413-418, 1995.
174. Krumholz, A., Sung, G. Y., Fisher, R. S., Barry, E., Bergey, G. K., and Grattan, L. M., Complex partial status epilepticus accompanied by serious morbidity and mortality, Neurology, 45, 1499-1504, 1995.
175. Theodore, W. H., Albert P., Stertz, B., Malow, B., Ko, D., White, S., Flamini, R., and Ketter, T., Felbamate monotherapy: implications for antiepileptic drug development, Epilepsia, 36, 1105-1110, 1995.
176. Bourgeois, B. F., Felbamate, Semin. Pediatr. Neurol., 4, 3-8, 1997.
177. Lee, T. J., Carney, C. N., Lapis, J. L., Higgins, T., and Fallon, H. J., Diphenylhydantoin-induced hepatic necrosis. A case study, Gastroenterology, 70, 422-424, 1976.
178. Mockli, G., Crowley, M., Stern, R., and Warnock, M. L., Massive hepatic necrosis in a child after administration of phenobarbital, Am. J. Gastroenterol., 84, 820-822, 1989.
179. Rubin, R., Sulfasalazine-induced fulminant hepatic failure and necrotizing pancreatitis, Am. J. Gastroenterol., 89, 789-791, 1994.
180. Shaefer, M. S., Edmunds, A. L., Markin, R. S., Wood, R. P., Pillen, T. J., and Shaw, B. W., Jr., Hepatic failure associated with imipramine therapy, Pharmacotherapy, 10, 66-69, 1990.
181. Knable, M. B. and Rickler, K., Psychosis associated with felbamate treatment, J. Clin. Psychopharmacol., 15, 292-293, 1995.
182. Hill, R. R., Stagno, S. J., and Tesar, G. E., Secondary mania associated with the use of felbamate, Psychosomatics, 36, 404-406, 1995.
183. McConnell, H., Snyder, P. J., Duffy, J. D., Weilburg, J., Valeriano, J., Brillman, J., Cress, K., and Cavalier, J., Neuropsychiatric side effects related to treatment with felbamate, J. Neuropsych. Clin. Neurosci., 8, 341-346, 1996.
184. Rivinus, T. M., Psychiatric effects of the anticonvulsant regimens, J. Clin. Psychopharmacol. 2, 165-192, 1982.
185. Schmidt, S. and Schmitz-Buhl, M., Signs and symptoms of carbamazepine overdose, J. Neurol., 242, 169-173, 1995.
186. Trimble, M. R., ed., The Psychopharmacology of Epilepsy, John Wiley & Sons, New York, NY, 1985.
187. Sunder, T. R., Meeting the challenge of epilepsy in persons with multiple handicaps, J. Child Neurol, 12, Suppl. 1, S38-S43, 1997.
188. Trimble, M. R., Psychiatric aspects of epilepsy, Psychiatr. Dev., 5, 285-300, 1987.
189. Gay, P. E., Mecham, G. F., Coskey, J. S., Sadler, T., and Thompson, J. A., Behavioral effects of felbamate in childhood epileptic encephalopathy (Lennox-Gastaut syndrome), Psychol. Rep., 77, 1208-1210, 1995.
190. Bergen, D. C., Ristanovic, R. K., Waicosky, K., Kanner, A., and Hoeppner, T. J., Weight loss in patients taking felbamate, Clin. Neuropharmacol., 18, 23-27, 1995.